These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 1374922)

  • 1. Azelastine potentiates the prostaglandin-induced increase of cyclic AMP content in human platelets and in guinea-pig alveolar macrophages.
    Hatmi M; Havet N; Vargaftig BB; Bachelet M
    Prostaglandins; 1992 May; 43(5):457-72. PubMed ID: 1374922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of azelastine on the intracellular Ca2+ mobilization in guinea pig peritoneal macrophages.
    Nakamura T; Nishizawa Y; Sato T; Yamato C
    Eur J Pharmacol; 1988 Mar; 148(1):35-41. PubMed ID: 2898372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of antiaggregating activity of adenosine by a phosphodiesterase inhibitor, EG626 (oxagrelate), in human platelets in vitro.
    Azuma H; Takashima Y; Ishikawa M; Yamakado T
    Jpn J Pharmacol; 1984 Feb; 34(2):159-70. PubMed ID: 6205194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory effect of azelastine hydrochloride on synthesis and release of platelet activating factor from human alveolar macrophages.
    Shindo K; Machida M; Hirai Y; Fukumura M
    Prostaglandins Leukot Essent Fatty Acids; 1997 Dec; 57(6):561-6. PubMed ID: 9431823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on antiplatelet effects of OP-41483, a prostaglandin I2 analog, in experimental animals. II. Mechanism of its antiplatelet effect.
    Fujitani B; Wakitani K
    Jpn J Pharmacol; 1990 May; 53(1):25-33. PubMed ID: 2161965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
    Merritt JE; Hallam TJ; Brown AM; Boyfield I; Cooper DG; Hickey DM; Jaxa-Chamiec AA; Kaumann AJ; Keen M; Kelly E
    Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of cyclic AMP and cyclic GMP phosphodiesterase inhibitors on the superoxide burst of guinea-pig peritoneal macrophages.
    Turner NC; Wood LJ; Burns FM; Gueremy T; Souness JE
    Br J Pharmacol; 1993 Apr; 108(4):876-83. PubMed ID: 8387385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High concentrations of exogenous arachidonate inhibit calcium mobilization in platelets by stimulation of adenylate cyclase.
    Kowalska MA; Rao AK; Disa J
    Biochem J; 1988 Jul; 253(1):255-62. PubMed ID: 2458717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclic AMP and cyclic GMP phosphodiesterase inhibition by an antiplatelet agent, 6-[(3-methylene-2-oxo-5-phenyl-5-tetrahydrofuranyl)methoxy)quinol inone (CCT-62).
    Liao CH; Tzeng CC; Teng CM
    Eur J Pharmacol; 1998 May; 349(1):107-14. PubMed ID: 9669503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction by arachidonic acid of prostaglandin I2-induced cyclic AMP formation. Involvement of prostaglandins E2 and F2 alpha.
    Faili A; Randon J; Vargaftig BB; Hatmi M
    Biochem Pharmacol; 1993 May; 45(9):1815-20. PubMed ID: 8388209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase.
    Wu CC; Ko FN; Kuo SC; Lee FY; Teng CM
    Br J Pharmacol; 1995 Oct; 116(3):1973-8. PubMed ID: 8640334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model of prostaglandin-regulated cyclic AMP metabolism in intact platelets: examination of time-dependent effects on adenylate cyclase and phosphodiesterase activities.
    Ashby B
    Mol Pharmacol; 1989 Dec; 36(6):866-73. PubMed ID: 2481225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions between prostaglandin E2 and inhibitors of platelet aggregation which act through cyclic AMP.
    Gray SJ; Heptinstall S
    Eur J Pharmacol; 1991 Feb; 194(1):63-70. PubMed ID: 1647965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of adenylate cyclase by adenosine analogues in preparations of broken and intact human platelets. Evidence for the unidirectional control of platelet function by cyclic AMP.
    Haslam RJ; Davidson MM; Desjardins JV
    Biochem J; 1978 Oct; 176(1):83-95. PubMed ID: 215136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of TRK-100, a stable prostacyclin analogue, on regulation of cyclic AMP metabolism in platelets.
    Nogimori K; Kajikawa N; Nishio S; Yajima M
    Prostaglandins; 1989 Feb; 37(2):205-12. PubMed ID: 2543034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between PAF-acether and drugs that stimulate cyclic AMP in guinea-pig alveolar macrophages.
    Bachelet M; Adolfs MJ; Masliah J; Bereziat G; Vargaftig BB; Bonta IL
    Eur J Pharmacol; 1988 Apr; 149(1-2):73-8. PubMed ID: 2840303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukotriene D4 receptors are not negatively coupled to adenylyl cyclase in guinea-pig lung parenchyma.
    Giembycz MA; Diamond J; Rodger IW
    Br J Pharmacol; 1993 Mar; 108(3):824-32. PubMed ID: 8385538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP.
    Fisch A; Michael-Hepp J; Meyer J; Darius H
    Eur J Pharmacol; 1995 May; 289(3):455-61. PubMed ID: 7556414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentiation of aggregation and inhibition of adenylate cyclase in human platelets by prostaglandin E analogues.
    Matthews JS; Jones RL
    Br J Pharmacol; 1993 Feb; 108(2):363-9. PubMed ID: 8448586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of PGE1-induced increase in cyclic AMP by chemotactic peptide and Ca2+ ionophore through calmodulin-dependent processes.
    Ishitoya J; Takenawa T
    J Immunol; 1987 Feb; 138(4):1201-7. PubMed ID: 2433345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.